FICHIT

Je m'inscris

ABIVAX

0/5 (0 note(s))
Note donnée : aucune
Paris
137
ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world’s most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B.
ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B.  ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months.
EHRLICH Hartmut
www.abivax.com
ABVX:FP

Fiche créée le 10/04/2016 par Guillaume   vue 17 fois.